THE SMALL GTPase RhoA is involved in many actinbased cellular processes including cell adhesion, cytokinesis, stress fiber formation, and smooth muscle contractility (reviewed in Refs. 14 and 37). RhoA also modulates transcriptional activity of serum response factor (SRF), a homodimeric MADS box-containing protein (17) . SRF has been shown to be required for expression of the skeletal and cardiac ␣-actin genes and smooth muscle ␣-and ␥-actin genes, which are among the earliest markers for mesoderm-derived skeletal, cardiac, and smooth muscle differentiation (4, 8, 28) . We have previously shown that RhoA activates skeletal ␣-actin transcription in C 2 C 12 myoblasts through SRF and that stable expression of a dominant negative mutant of RhoA reduces terminal differentiation, in part, through its effect on SRF activity (40) . A recent report has also shown that inhibition of Rho family proteins by the GDP dissociation inhibitor RhoGDI suppresses myogenesis in C 2 C 12 myoblasts (34) .
One way to investigate the mechanisms by which RhoA is involved in myogenesis is to determine whether RhoA interacts with signal pathways previously shown to be important in muscle differentiation. RhoA has been shown to function both upstream and downstream of integrins in the context of focal adhesion formation and stress fiber assembly (reviewed in Ref. 5 ). All integrins are heterodimeric transmembrane receptors consisting of an ␣-subunit associated with a ␤-subunit and mediating association between extracellular matrix (ECM) and cytoskeleton elements. Experimental evidence for the importance of integrin interaction with ECM proteins during muscle differentiation was elucidated in fibronectin null mice, which are defective in forming somites (10) . Myotube formation and myogenic differentiation were also blocked in myoblast cultures treated with antibodies to integrins (25) . In addition, mice lacking focal adhesion kinase (FAK), an important mediator of integrin signaling, displayed a general defect in mesoderm formation, a phenotype similar to that observed in fibronectin-deficient mice (18) . Moreover, levels of expression of several ␤ 1 -integrins such as ␣ 4 ␤ 1 , ␣ 5 ␤ 1 , and ␣ 7 ␤ 1 and their isoforms such as ␣ 7A , ␣ 7B , ␤ 1A , and ␤ 1D are developmentally regulated in skeletal muscle and heart (reviewed in Ref. 13) , suggesting that integrin switches may be involved in myogenesis and heart development. In contrast to the common ␤ 1A -isoform that is widely expressed and prominent in prefusion myoblasts, the ␤ 1D -isoform is restricted to skeletal muscle and heart and becomes the major isoform in these tissues (3, 38) , suggesting that it may have an important function in these tissues.
Another potential signaling pathway interacting with RhoA during muscle differentiation is signaling through phosphatidylinositol (PI) 3-kinase. Recent studies have shown that PI 3-kinase plays an important role in muscle differentiation and is required for insulin-like growth factor (IGF)-induced muscle differentiation (19) (20) (21) . In addition, integrin-mediated signaling pathways also activate PI 3-kinase that is translocated to the cytoskeleton, which involves specific interactions of p85 subunit with actin filament and FAK (12) . Moreover, PI 3-kinase functions downstream of RhoA in platelet and Swiss 3T3 cells (22, 42) .
We examined whether ␤ 1 -integrin-, FAK-, and PI 3-kinase-mediated myogenic signaling pathways cross talk with the RhoA signaling pathway to regulate SRF-dependent muscle gene expression such as skeletal ␣-actin promoter activity. In the present study, we found that ECM proteins and the ␤ 1 -integrin affect RhoA-dependent activation of the skeletal ␣-actin in myoblasts. Interestingly, the muscle-specific ␤ 1D -integrin potentiates RhoA-dependent activation of the skeletal ␣-actin promoter and inhibits RhoA-dependent activation of the c-fos promoter, suggesting that RhoA regulates these two SRF-dependent promoter activities through different signaling pathways. Moreover, FAK and PI 3-kinase are required for RhoA-dependent activation of the ␣-actin promoter. A dominant negative mutant of FAK [FAK-related non-kinase (FRNK)] inhibits activation of the ␣-actin promoter by RhoA. Both wortmannin and a dominant negative mutant of PI 3-kinase (⌬p85) inhibit ␣-actin promoter activity induced by RhoA. In addition, RhoA increases PI 3-kinase activity associated with exogenous p85 subunit. These results suggest that RhoA, ␤ 1 -integrin, FAK, and PI 3-kinase serve together as an important signaling network in regulating muscle-specific gene expression.
MATERIALS AND METHODS
Plasmid constructs. The reporter plasmid SK-luc contains the avian skeletal ␣-actin promoter from Ϫ398 to ϩ25 bp linked to the firefly luciferase reporter gene (24) . The reporter plasmid c-fos-SRE-luc contains the c-fos serum response element (SRE) region (Ϫ318 to Ϫ291 bp) (24) . The expression plasmids pCGN-RhoA and pCGN-V14-RhoA were constructed as previously described (40) . The cDNA constructs for fulllength avian FAK and the truncated COOH-terminal FAK (FRNK) were cloned into the pCMV-Myc vector and were kindly provided by Dr. J. Thomas Parsons (31) . The expression plasmids pCMVIL2R, pCMVIL2R␣5, and pCMVIL2R␤1 containing the human interleukin-2 receptor extracellular and transmembrane domains in combination with the intracellular domain for either ␣ 5 -or ␤ 1 -integrin were kindly provided by Drs. Susan LaFlamme and Kenneth Yamada (23) . The full-length cDNA constructs for human ␤ 1A -and ␤ 1D -integrins cloned into the pECE vector were the kind gift of Dr. Alexey Belkin (3) . The expression plasmids SR␣-p85 and SR␣-⌬p85, containing the wild type (p85) and the mutant bovine p85␣-subunit lacking the binding site for the p110 catalytic subunit of PI 3-kinase (⌬p85), respectively, were kindly provided by Dr. Masato Kasuga (15) .
Tissue culture, plasmid DNA transfection, and reporter gene assays. C 2 C 12 mouse myoblasts (27) were maintained in DMEM (GIBCO-BRL) with 10% fetal bovine serum (FBS). Cells were plated at a density of 3 ϫ 10 5 cells in 60-mm tissue culture plates and were transfected after 24 h. Cells were transfected with ϳ1 µg of total plasmid DNA containing the indicated reporter plasmid (0.1 µg of SK-luc or c-fos-SRE-luc) with expression plasmids and balanced with parental expression vector. Transfections were performed using lipofectamine (GIBCO-BRL) according to the manufacturer's instructions. Cells were placed in DMEM with 10% FBS and harvested 48 h posttransfection. Luciferase activity and protein content were measured as previously described (24) . Luciferase activity was normalized to the total protein, and data were expressed as luciferase activity normalized to baseline reporter gene. All experiments were performed in duplicate and repeated three to five times. For experiments evaluating effects of ECM proteins on skeletal ␣-actin promoter activity, plates were coated overnight with rat tail collagen, fibronectin (20 µg/ml), and poly-L-lysine (10 µg/ml) and then blocked with 2% BSA for 2 h before plating. For experiments evaluating PI 3-kinase activity, cells were placed in medium with or without wortmannin (1 µM) and harvested 48 h posttransfection. The medium was replaced every 8 h because of the instability of wortmannin.
Protein expression analysis. Expression levels of cDNA expression plasmids were examined by Western blot analysis. Myoblasts on 60-mm plates were transiently transfected with 2 µg of each expression plasmid using lipofectamine. After 48 h, the cells were solubilized with lysis buffer (20 mM Tris, pH 7.5, 1% Triton X-100, 100 mM NaCl, 5 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 50 µg/ml antipain) for 30 min with shaking at 4°C. Cell lysates were then cleared by centrifugation. In the detection of Myc-tagged FAK and FRNK, whole cell protein extracts (50 µg) were run on an 8% SDS-PAGE gel, transferred to Immobilon membrane (Millipore), and probed with anti-Myc monoclonal antibody (Oncogene). In the detection of HA-tagged p85 or ⌬p85, cell extracts (200 µg) were incubated with anti-HA monoclonal antibody (2 µg/ml) at 4°C for 1 h. Immunoprecipitates were then collected on protein A/G-Sepharose (Santa Cruz), washed three times with lysis buffer, and separated on an 8% SDS-PAGE gel. The blots were then probed with polyclonal anti-p85 antibodies (Upstate Biotechnology). Enhanced chemiluminescence (Amersham) was used as the detection system. PI 3-kinase assay. HA-tagged p85 was immunoprecipitated from cell extracts of transiently transfected myoblasts as described above. PI 3-kinase activity was assayed by TLC as described previously (41) . Briefly, immunoprecipitates were incubated with 50 µl of reaction buffer containing PI (20 µg), 20 mM Tris (pH 7.5), 100 mM NaCl, 10 mM MgCl 2 , 50 µM ATP, and [␥-32 P]ATP (10 µCi) for 15 min with constant agitation at 37°C. The reaction was terminated by the addition of 20 µl of 6 N HCl, and lipids were extracted by the addition of 160 µl of CHCl 3 -CH 3 OH (1:1) and separated by TLC in CHCl 3 -CH 3 OH-H 2 O-NH 4 OH (60:47:11.3:2). The TLC plate was dried and autoradiographed, and radioactivity of 32 P-labeled PI 3-phosphate spots was determined by PhosphorImaging analysis (Molecular Dynamics).
Statistics. Data are expressed as means Ϯ SE, relative to values for parallel cultures of control vector-transfected cells. Student's t-test was used for data comparison, with a significance level of P Ͻ 0.05.
RESULTS
ECM proteins regulate activation of the skeletal ␣-actin promoter by RhoA. We have shown that V14-RhoA, a constitutively active RhoA mutant, activates skeletal ␣-actin promoter up to seven times the basal level, whereas N19-RhoA, a dominant negative mutant, represses the basal level (control vector-transfected cells) up to 40% in a dose-dependent manner in myoblasts (40) . We have shown that activation of the skeletal ␣-actin promoter by RhoA depends on an intact SRE and a functional SRF (40) . To investigate the possible interactions between integrin and RhoA signaling pathways during muscle differentiation, we first examined the role of integrin-independent (poly-L-lysine) and -dependent (collagen and fibronectin) cell adhesion on skeletal ␣-actin promoter activity in concert with RhoA. As shown in Fig. 1 , activation of the skeletal ␣-actin promoter by V14-RhoA was significantly increased in myoblasts attached to collagen (P ϭ 0.046) or fibronectin (P ϭ 0.007) but was decreased in cells attached to poly-L-lysine compared with myoblasts plated on uncoated dishes. These results indicate that certain ECM proteins may potentiate RhoA-mediated activation of the skeletal ␣-actin promoter.
Disruption of ␤ 1 -integrin signaling inhibits skeletal ␣-actin promoter activity stimulated by RhoA. Collagen and fibronectin interact with the ␤ 1 -subfamily of integrins that have been shown to play a critical role in muscle differentiation (10, 25) . We examined whether ␤ 1 -integrin signaling mediates RhoA-dependent activation of the skeletal ␣-actin promoter. A chimeric protein (IL2R-␤1) composed of the extracellular and transmembrane domains of interleukin-2 receptor and the cytoplasmic domain of ␤ 1A -integrin was used to disrupt ␤ 1 -integrin signaling ( Fig. 2A) (23) . A similar construct (IL2R-␣5) containing the cytoplasmic domain of ␣ 5 -integrin and the expression vector served as controls. Our results show that IL2R-␤1 significantly reduced the activity of the promoter in V14-RhoA-transfected cells (P ϭ 0.027) with no effect on the basal activity of the promoter (P ϭ 0.382). The noninteractive IL2R-␣5 control had no significant effect on the activity of the promoter in both V14-RhoA-transfected (P ϭ 0.338) and control vector-transfected cells (P ϭ 0.171) (Fig.  2B) . Thus results of this experiment indicate that disruption of ␤ 1 -integrin-mediated signaling interferes with RhoA-dependent activation of the skeletal ␣-actin promoter in myoblasts.
Muscle-specific ␤ 1D -isoform potentiates activation of the skeletal ␣-actin promoter by RhoA. The ␤ 1A -and ␤ 1D -integrin isoforms are very similar and differ by only 13 amino acids in their cytoplasmic tail (3, 38) . We examined whether these two integrin isoforms have different regulatory roles in skeletal ␣-actin promoter activity. Expression of either of these integrins alone in myoblasts did not result in increased activity of the skeletal ␣-actin promoter. Coexpression of ␤ 1D -integrin, but not ␤ 1A -integrin, with V14-RhoA significantly increased RhoA-dependent activation of the SK-luc reporter plasmid (P ϭ 0.034) (Fig. 3A) , indicating a selective role in mediating RhoA signaling in regulating skeletal ␣-actin gene expression. It is worth noting that exogenous expression of ␤ 1A -integrin had no effect on the activation of the skeletal ␣-actin promoter by RhoA, whereas a dominant negative ␤ 1A -isoform inhibited this activation. These results suggest that the endogenous level of ␤ 1A -integrin is not a limiting factor for activation of the ␣-actin promoter by RhoA in myoblasts.
We have previously observed that RhoA activates both skeletal ␣-actin and c-fos-SRE promoters in myoblasts (40) . Interestingly, in contrast to its stimulatory effect on skeletal ␣-actin promoter activation by RhoA, ␤ 1D -integrin inhibited activation of c-fos-SRE by RhoA (P ϭ 0.004) (Fig. 3B) , indicating that RhoA regulates these two SRF-dependent promoter activities through different means.
FAK is required for skeletal ␣-actin promoter activity. We next examined whether FAK, an important downstream mediator of integrin signaling, would also be a mediator of RhoA signaling in skeletal ␣-actin promoter activation. A truncated mutant of FAK, FRNK (Fig. 4A) , which contains the COOH-terminal domain of FAK without the kinase domain, was previously shown (31) to act as a negative inhibitor. Expression of FRNK alone reduced basal level of the skeletal ␣-actin promoter activity (P ϭ 0.025). It also reduced activation of the ␣-actin promoter by V14-RhoA (P ϭ 0.029) and coactivation by V14-RhoA and ␤ 1D -integrin (P ϭ 0.026) (Fig. 4B) , indicating that FAK may be required for efficient activation of the ␣-actin promoter. However, expression of exogenous FAK did not significantly stimulate the ␣-actin promoter in V14-RhoA-transfected (P ϭ 0.427) and control vector-transfected cells (P ϭ 0.469), perhaps indicating that the level of endogenous FAK might not be a limiting factor for the activation of the skeletal ␣-actin promoter under these conditions. Expression of exogenous FAK and FRNK was confirmed by Western analysis (Fig. 4C) .
PI 3-kinase is required for skeletal ␣-actin promoter activity. PI 3-kinase is another potential mediator of RhoA signaling in myogenesis. Two approaches were taken to determine whether PI 3-kinase is required for RhoA-mediated activation of the skeletal ␣-actin promoter. First, wortmannin was added to muscle cultures to inhibit PI 3-kinase activity (36) . Second, PI 3-kinase activity was inhibited by expression of cotransfected plasmid expressing a dominant negative mutant of the p85 subunit (⌬p85) that lacks the binding site for the p110 catalytic subunit (15) .
As shown in Fig. 5 , 1 µM wortmannin significantly inhibited RhoA-mediated activation of the skeletal ␣-actin promoter. Another chemical inhibitor of PI 3-kinase, LY-294002, also was found to inhibit activation of the actin promoter by RhoA (data not shown). Because wortmannin may not be PI 3-kinase specific, we then evaluated the effect of ⌬p85, a dominant negative PI 3-kinase mutant, on skeletal ␣-actin promoter activation (Fig. 6A) . The expression plasmid SR␣-⌬p85 was transfected into C 2 C 12 myoblasts, and its effects were compared with the empty vector SR␣ and the expression plasmid SR␣-p85 encoding the wildtype p85 (Fig. 6B) . Expression of ⌬p85 reduced the basal activity of skeletal ␣-actin promoter (P ϭ 0.028) and the activity stimulated by V14-RhoA (P ϭ 0.021), whereas the wild-type p85 had no significant effect on the promoter activity under these conditions (P ϭ 0.125 or 0.345, respectively). Expression of these recombinant proteins was confirmed by Western blot analysis (Fig. 6C ). These observations are consistent with the results obtained with wortmannin, indicating that PI 3-kinase may mediate RhoA-dependent activation of the skeletal ␣-actin promoter.
Finally, to investigate the mechanism by which PI 3-kinase modulates RhoA activation of the skeletal ␣-actin promoter, we examined whether V14-RhoA increased PI 3-kinase activity in myoblasts. HA epitopetagged p85 or ⌬p85 was expressed with or without V14-RhoA in myoblasts. These exogenous proteins were then immunoprecipitated with anti-HA antibody, which does not affect catalytic activity of immunoprecipitated PI 3-kinase, and assayed for lipid kinase activity, which was normalized to the p85 content in the immunocomplex determined by Western blot analysis (Fig. 7A) . The activity of PI 3-kinase activity associated with the wildtype p85 was significantly increased in the presence of V14-RhoA (P ϭ 0.015, n ϭ 3), whereas that associated with ⌬p85 was not affected (Fig. 7B ). One possible mechanism by which RhoA increases PI 3-kinase activity is to increase its association with FAK. However, by Western blot analysis, we found only a minor portion of the endogenous p85 subunit of PI 3-kinase associated with FAK (Ͻ10%), and this interaction was not increased by V14-RhoA. Similarly, PI 3-kinase activity coimmunoprecipitated with FAK was not increased by V14-RhoA. These observations suggest that PI 3-kinase might not be immediately downstream of FAK in regulating RhoA-dependent activation of the skeletal ␣-actin promoter.
DISCUSSION
Integrin-mediated signaling regulates RhoA-dependent activation of the skeletal ␣-actin promoter. We examined whether RhoA interacts with signaling pathways involved in muscle differentiation. The integrinmediated signaling pathway was of particular interest because considerable amounts of evidence support a critical role for integrin-mediated signals in muscle differentiation, and functional interactions between RhoA and integrin signaling pathways have been extensively investigated in focal adhesion formation and stress fiber assembly. We showed several lines of evidence for functional interactions between RhoA and integrin-mediated signals in regulating muscle gene expression: 1) extracellular matrix proteins such as collagen and fibronectin enhanced RhoA-dependent activation of the skeletal ␣-actin promoter; 2) a dominant negative mutant of ␤ 1 -integrin reduced activation of the ␣-actin by RhoA; and 3) the muscle-specific ␤ 1 -integrin ␤ 1D -isoform was found to enhance RhoA- 6 . A dominant negative mutant of PI 3-kinase reduces activation of skeletal ␣-actin promoter by RhoA. A: schematic diagram of wild type (p85) and dominant negative mutant (⌬p85). B: C 2 C 12 myoblasts were transfected with 0.1 µg of SK-luc together with 0.25 µg of V14-RhoA, 0.5 µg of p85, or 0.5 µg of ⌬p85 expression plasmid alone or in combination as indicated. Data are presented as described in Fig. 1 legend. *Significantly different from control vector-transfected cells (P Ͻ 0.05). C: expression of p85 and ⌬p85 was analyzed by immunoprecipitation of cell extracts using anti-hemagglutinin (HA) antibody followed by Western blot analysis using polyclonal anti-p85 antibodies.
dependent activation of the skeletal ␣-actin promoter while repressing c-fos promoter activity.
In contrast to the common ␤ 1A -isoform, which is widely expressed, the ␤ 1D -isoform is restricted to skeletal muscle and heart and is the major isoform in these tissues, suggesting that it may have an important function in these tissues. Expression of ␤ 1D -isoform in C 2 C 12 myoblasts represses myoblast replication, suggesting that ␤ 1D -isoform may play a role in myoblast withdrawal from the cell cycle (2). However, mice lacking the ␤ 1D -isoform (having only ␤ 1A -isoform) form normal mature muscle without obvious histological or ultrastructural abnormality (1) . Our observation that ␤ 1D -isoform increased RhoA-dependent activation of the skeletal ␣-actin promoter, whereas ␤ 1A -isform was ineffectual, indicates selective functional interaction between RhoA and this muscle-specific isoform in regulating muscle-specific gene expression. Our finding that ␤ 1D -isoform inhibits activation of c-fos-SRE by RhoA indicates that RhoA may act through at least two different pathways to regulate skeletal ␣-actin and c-fos promoters.
FAK is required for efficient activation of the skeletal ␣-actin promoter. FAK is an important downstream signaling molecule of integrins, because it has been found to be the most prominent of the tyrosinephosphorylated proteins in cells responding to integrin activation (reviewed in Ref. 5) . Functional interactions between RhoA and FAK have been demonstrated in the formation of the focal adhesion complex (9) . It has been proposed that RhoA and FAK interact through the clustering of integrin induced by RhoA activation that may thereby activate FAK (29) . This may occur through a direct interaction, because FAK has recently been found to associate with Graf, a Rho GTPase-activating protein (16) . However, a role for FAK in muscle differentiation has not been reported. The present study shows that FAK modulates RhoA-dependent activation of the skeletal ␣-actin promoter, suggesting a functional relationship between RhoA and FAK in regulating musclespecific gene expressions in myoblasts. In primary cultured chicken myoblasts, we observed that FRNK reduced myosin heavy chain expression in mature myotubes (unpublished results), also supporting a role for FAK in myodifferentiation.
PI 3-kinase is required for efficient activation of the skeletal ␣-actin promoter. Recent reports have shown that PI 3-kinase plays a vital role in myogenesis (19) (20) (21) . Functional interactions between RhoA and PI 3-kinase have been observed between RhoA and PI 3-kinase in platelet and Swiss 3T3 cells, where RhoA is required for PI 3-kinase activation in response to extracellular stimuli (22, 42) . Our results demonstrate that PI 3-kinase may be a mediator of the RhoA signaling pathway in regulating muscle-specific gene expression. Wortmannin, a known inhibitor of PI 3-kinase, and a dominant negative mutant of the p85 subunit of PI 3-kinase both inhibited RhoA-dependent activation of the skeletal ␣-actin promoter. PI 3-kinase activity associated with cotransfected p85 was also increased by V14-RhoA in myoblasts.
The mechanism by which PI 3-kinase interferes with RhoA signaling remains to be determined. It has been suggested that PI 3-kinase is involved in the integrinmediated signal pathway, because PI 3-kinase is activated following cell attachment to ECM proteins and is then translocated to the cytoskeleton, which involves specific interactions of p85 subunit with actin filament and FAK (12) . However, we observed that only a minor portion of the endogenous p85 subunit of PI 3-kinase was associated with FAK (Ͻ10%), and this interaction was not increased by V14-RhoA, suggesting that RhoA may activate the PI 3-kinase signaling pathway through other mechanisms. In addition, RhoA may also increase the level of the PI 3-kinase substrate PI 4,5-bisphosphate through activation of PI 4-phosphate 5-kinase Fig. 7 . RhoA activates PI 3-kinase activity in myoblasts. A: C 2 C 12 myoblasts were transfected with 2 µg of HA-p85 or HA-⌬p85 expression plasmid alone or together with 2 µg of HA-V14-RhoA expression plasmid. HA-p85 was immunoprecipitated from cell extracts and divided equally into 2 aliquots; 1 aliquot was assayed for PI 3-kinase activity by measuring 32 P-labeled PI 3-phosphate level (PIP) by TLC (top), and the other aliquot was analyzed by Western blot for p85 expression level (middle) with anti-p85 antibody. V14-RhoA expression in cell extracts was also confirmed by Western blot with anti-HA antibody (bottom). B: PI 3-kinase activity was normalized to the p85 content in the immunocomplex. Values are means Ϯ SE and are expressed relative to values for cells transfected with HA-⌬p85 without V14-RhoA. HA-⌬p85 is unable to associate with catalytic subunit. *Significantly different from HA-⌬p85-transfected cells (P Ͻ 0.05). (30) . It has been shown that IGF-dependent signal pathways through association with insulin receptor substrate 1 activate PI 3-kinase (20) . Whether IGFdependent activation of PI 3-kinase is involved in regulating the RhoA-dependent signal pathway in muscle cells is under investigation.
RhoA regulates SRF-dependent gene expressions through different signaling pathways in myoblasts and fibroblasts. SRF mediates RhoA signaling to the skeletal ␣-actin promoter through the proximal SRE site of the promoter (40) . Since the discovery of regulation of c-fos transcription by RhoA through SRF in fibroblasts, considerable progress has been made in identifying signaling pathways involved in RhoA activation of c-fos promoter. Regulators of actin dynamics such as LIM kinases (where LIM is an acronym of the three gene products Lin-11, Isl-1 and Mec-3) (33), nuclear factor-B (NF-B) and CCAAT/enhancer-binding protein transcription factors (26) , protein kinases C-␣ and -⑀ (32), and Rho kinases (7) have been shown to mediate RhoA signaling to c-fos SRE in fibroblasts. In addition, the PI 3-kinase inhibitor wortmannin had no significant effect on the c-fos promoter activation by RhoA (17) , and PI 3-kinase was reported to function upstream RhoA to activate c-fos promoter (39) in fibroblasts. In C 2 C 12 myoblasts, treatment with the Rho kinase inhibitor Y27632 (35) had no effect on myoblast differentiation and on activation of the skeletal ␣-actin promoter by RhoA (unpublished results). An NF-B inhibitor, IB␣S32A/S36A, had no effect on the activation of the skeletal ␣-actin by RhoA (unpublished results). We are currently evaluating whether there is a role for LIM kinases in RhoA signaling to skeletal ␣-actin in myoblasts. These observations suggest that RhoA signaling to c-fos promoter in fibroblasts may be different from RhoA signaling to skeletal ␣-actin promoter in myoblasts. We have previously shown that activation of cardiac ␣-actin promoter by SRF is regulated by the formation of a functional complex of SRF with other muscle-specific cofactors such as Nkx2.5 (6) and GATA4 (unpublished results). SRF also associates with myogenic factors such as myogenin and MyoD (11) . These observations may explain the discrepancies observed for nonmuscle c-fos versus myogenic SREdependent activities and suggest that RhoA activation of SRF-dependent muscle gene expression may involve recruitment of muscle-specific accessory factors that are susceptible to other myogenic signals.
In conclusion, regulation of muscle differentiation by RhoA is a complex process under the control of several regulatory pathways. These signaling pathways involve integrin interactions with the ECM proteins, FAK-mediated signal transduction, and generation of phospholipids. RhoA, a signaling molecule implicated in a diverse set of cellular functions, regulates muscle gene expression through cross talk with these signal pathways. Because SRF activation by RhoA appears to be regulated by different signaling pathways in fibroblasts and myoblasts, we propose that activation of SRF-dependent muscle gene expression by RhoA depends on the presence and activity of muscle-specific cofactors. Further studies are necessary to establish the physiological significance of the RhoA signaling network in muscle development, regeneration, and hypertrophy.
